Urata et al. reported a study of 243 early RA patients who were divided into routine care, DAS28 driven therapy, MMP-3 driven therapy or both DAS28 and MMP-3 driven therapy groups and the result of one-year follow-up showed that the MMP-3 driven therapy group had the greatest proportion to achieve radiographic non-progression among these four groups, which implied that serum MMP-3 might be a supplemental predictor of radiographic progression in clinical practice [25]. This evidence concerns the gene MMP3 and rheumatoid arthritis.